Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
I. Backhaus,
D. Hermsen,
J. Timm,
F. Boege,
N. Lübke,
T. Degode,
K. Göbels and
N. Dragano,
"SARS-CoV-2 seroprevalence and determinants of infection in young adults: A population-based seroepidemiological study",
Public Health,
2022.
| DOI: | https://doi.org/10.1016/j.puhe.2022.03.009 |
P. Arora and
et al,
"SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination",
Cell Reports,
vol. 39,
pp. 110754,
2022.
| DOI: | 10.1016/j.celrep.2022.110754 |
S. F,
T. C,
D. F,
R. RM,
M. M,
R. C,
A. F,
K. P,
M. HJ,
L. LJ,
H. ET,
G. D,
T. B,
S. N,
S. LE,
K. F,
P. T,
W. M and
Z. T,
"Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months.",
Respiratory medicine,
Jan.
2022.
Abstract:
Prospektive und longitudinale Daten zur Lungenverletzung über ein Jahr nach akuter Coronavirus-Krankheit 2019 (COVID-19) sind spärlich. Die Patienten mit akutem COVID-19 wurden in ein laufendes, prospektives Beobachtungsstudium eingeschrieben und 6 Wochen, 3, 6 und 12 Monate nach Beginn der Symptome von COVID-19 untersucht. Chest CT-Scans, Lungenfunktion und Symptome, die von St. Georges Respiratory Questionnaire bewertet wurden, wurden verwendet, um Atembeschränkungen zu bewerten. Die Patienten wurden nach Schwere der akuten COVID-19 gestreut. Das mittlere Alter aller Patienten betrug 57 Jahre, 37,8% waren weiblich. Höheres Alter, männliches Geschlecht und höheres BMI wurden mit akuter COVID-19 Schwere verbunden (p < 0,0001, 0,001 bzw. 0,004). Auch die Lungenbeschränkung und die verringerte Kohlenmonoxiddiffusionskapazität war mit der Krankheitsschwere verbunden. Bei Patienten mit eingeschränkter und beeinträchtigter Diffusionskapazität verbesserte sich FVC über 12 Monate von 61,32 bis 71,82, DC von 68,92 bis 76,95, D<sub>LCO</sub> von 60,18 bis 68,98 und K<sub>CO</sub> von 81,28 bis 87,80 (prozentige prognostizierte Werte; p = 0,002, 0,045, 0,0002 und 0,0005). Der CT-Score der Lungenbeteiligung in der akuten Phase war mit einer Restriktion und Verringerung der Diffusionskapazität im Anschluss verbunden. Atemwegserkrankungen verbesserten sich bei Patienten in höheren Schweregruppen während der Folge, nicht aber bei Patienten mit zunächst milder Erkrankung. Schwere des Atemversagens während der COVID-19 korreliert mit dem Grad der Lungenfunktion Beeinträchtigung und Atmungsqualität des Lebens im Jahr nach akuter Infektion.
| DOI: | 10.1016/j.rmed.2021.106709 |
Abstract:
Prospektive und longitudinale Daten zur Lungenverletzung über ein Jahr nach akuter Coronavirus-Krankheit 2019 (COVID-19) sind spärlich. Die Patienten mit akutem COVID-19 wurden in ein laufendes, prospektives Beobachtungsstudium eingeschrieben und 6 Wochen, 3, 6 und 12 Monate nach Beginn der Symptome von COVID-19 untersucht. Chest CT-Scans, Lungenfunktion und Symptome, die von St. Georges Respiratory Questionnaire bewertet wurden, wurden verwendet, um Atembeschränkungen zu bewerten. Die Patienten wurden nach Schwere der akuten COVID-19 gestreut. Das mittlere Alter aller Patienten betrug 57 Jahre, 37,8% waren weiblich. Höheres Alter, männliches Geschlecht und höheres BMI wurden mit akuter COVID-19 Schwere verbunden (p < 0,0001, 0,001 bzw. 0,004). Auch die Lungenbeschränkung und die verringerte Kohlenmonoxiddiffusionskapazität war mit der Krankheitsschwere verbunden. Bei Patienten mit eingeschränkter und beeinträchtigter Diffusionskapazität verbesserte sich FVC über 12 Monate von 61,32 bis 71,82, DC von 68,92 bis 76,95, D<sub>LCO</sub> von 60,18 bis 68,98 und K<sub>CO</sub> von 81,28 bis 87,80 (prozentige prognostizierte Werte; p = 0,002, 0,045, 0,0002 und 0,0005). Der CT-Score der Lungenbeteiligung in der akuten Phase war mit einer Restriktion und Verringerung der Diffusionskapazität im Anschluss verbunden. Atemwegserkrankungen verbesserten sich bei Patienten in höheren Schweregruppen während der Folge, nicht aber bei Patienten mit zunächst milder Erkrankung. Schwere des Atemversagens während der COVID-19 korreliert mit dem Grad der Lungenfunktion Beeinträchtigung und Atmungsqualität des Lebens im Jahr nach akuter Infektion.
F. Steinbeis,
C. Thibeault,
F. Doellinger,
R. Ring,
M. Mittermaier,
C. Ruwwe-Glösenkamp,
P. Knape,
H. Meyer,
L. Lippert,
E. Helbig,
B. Temmesfeld,
N. Suttorp,
L. E. Sander,
F. Kurth,
T. Penzkofer,
M. Witzenrath,
T. Zoller and
D. Grund,
"Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months.",
Respir Med. 2022;191:106709.,
2022.
[en]
T. Bahmer,
C. Borzikowsky,
W. Lieb,
A. Horn,
L. Krist,
J. Fricke,
C. Scheibenbogen,
K. F. Rabe,
W. Maetzler,
C. Maetzler,
M. Laudien,
D. Frank,
S. Ballhausen,
A. Hermes,
O. Miljukov,
K. G. Haeusler,
N. E. E. Mokhtari,
M. Witzenrath,
J. J. Vehreschild,
D. Krefting,
D. Pape,
F. A. Montellano,
M. Kohls,
C. Morbach,
S. Störk,
J. Reese,
T. Keil,
P. Heuschmann,
M. Krawczak,
S. Schreiber and
N. group,
"Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study",
EClinicalMedicine,
vol. 51,
no. 101549,
pp. 101549,
Sep.
2022.
Elsevier BV.
Abstract:
Background: Post-COVID syndrome (PCS) is an important sequela of COVID-19, characterised by symptom persistence for >3 months, post-acute symptom development, and worsening of pre-existing comorbidities. The causes and public health impact of PCS are still unclear, not least for the lack of efficient means to assess the presence and severity of PCS. Methods: COVIDOM is a population-based cohort study of polymerase chain reaction (PCR) confirmed cases of SARS-CoV-2 infection, recruited through public health authorities in three German regions (Kiel, Berlin, W"urzburg) between November 15, 2020 and September 29, 2021. Main inclusion criteria were (i) a PCR confirmed SARS-CoV-2 infection and (ii) a period of at least 6 months between the infection and the visit to the COVIDOM study site. Other inclusion criteria were written informed consent and age $\geq$18 years. Key exclusion criterion was an acute reinfection with SARS-CoV-2. Study site visits included standardised interviews, in-depth examination, and biomaterial procurement. In sub-cohort Kiel-I, a PCS (severity) score was developed based upon 12 long-term symptom complexes. Two validation sub-cohorts (W"urzburg/Berlin, Kiel-II) were used for PCS score replication and identification of clinically meaningful predictors. This study is registered at clinicaltrials.gov (NCT04679584) and at the German Registry for Clinical Studies (DRKS, DRKS00023742). Findings: In Kiel-I (n = 667, 57% women), 90% of participants had received outpatient treatment for acute COVID-19. Neurological ailments (61·5%), fatigue (57·1%), and sleep disturbance (57·0%) were the most frequent persisting symptoms at 6-12 months after infection. Across sub-cohorts (W"urzburg/Berlin, n = 316, 52% women; Kiel-II, n = 459, 56% women), higher PCS scores were associated with lower health-related quality of life (EQ-5D-5L-VAS/-index: r = -0·54/ -0·56, all p < 0·0001). Severe, moderate, and mild/no PCS according to the individual participant's PCS score occurred in 18·8%, 48·2%, and 32·9%, respectively, of the Kiel-I sub-cohort. In both validation sub-cohorts, statistically significant predictors of the PCS score included the intensity of acute phase symptoms and the level of personal resilience. Interpretation: PCS severity can be quantified by an easy-to-use symptom-based score reflecting acute phase disease burden and general psychological predisposition. The PCS score thus holds promise to facilitate the clinical diagnosis of PCS, scientific studies of its natural course, and the development of therapeutic interventions. Funding: The COVIDOM study is funded by the Network University Medicine (NUM) as part of the National Pandemic Cohort Network (NAPKON).
| DOI: | 10.1016/j.eclinm.2022.101549 |
| Pubmed: | 35875815 |
Abstract:
Background: Post-COVID syndrome (PCS) is an important sequela of COVID-19, characterised by symptom persistence for >3 months, post-acute symptom development, and worsening of pre-existing comorbidities. The causes and public health impact of PCS are still unclear, not least for the lack of efficient means to assess the presence and severity of PCS. Methods: COVIDOM is a population-based cohort study of polymerase chain reaction (PCR) confirmed cases of SARS-CoV-2 infection, recruited through public health authorities in three German regions (Kiel, Berlin, W"urzburg) between November 15, 2020 and September 29, 2021. Main inclusion criteria were (i) a PCR confirmed SARS-CoV-2 infection and (ii) a period of at least 6 months between the infection and the visit to the COVIDOM study site. Other inclusion criteria were written informed consent and age $\geq$18 years. Key exclusion criterion was an acute reinfection with SARS-CoV-2. Study site visits included standardised interviews, in-depth examination, and biomaterial procurement. In sub-cohort Kiel-I, a PCS (severity) score was developed based upon 12 long-term symptom complexes. Two validation sub-cohorts (W"urzburg/Berlin, Kiel-II) were used for PCS score replication and identification of clinically meaningful predictors. This study is registered at clinicaltrials.gov (NCT04679584) and at the German Registry for Clinical Studies (DRKS, DRKS00023742). Findings: In Kiel-I (n = 667, 57% women), 90% of participants had received outpatient treatment for acute COVID-19. Neurological ailments (61·5%), fatigue (57·1%), and sleep disturbance (57·0%) were the most frequent persisting symptoms at 6-12 months after infection. Across sub-cohorts (W"urzburg/Berlin, n = 316, 52% women; Kiel-II, n = 459, 56% women), higher PCS scores were associated with lower health-related quality of life (EQ-5D-5L-VAS/-index: r = -0·54/ -0·56, all p < 0·0001). Severe, moderate, and mild/no PCS according to the individual participant's PCS score occurred in 18·8%, 48·2%, and 32·9%, respectively, of the Kiel-I sub-cohort. In both validation sub-cohorts, statistically significant predictors of the PCS score included the intensity of acute phase symptoms and the level of personal resilience. Interpretation: PCS severity can be quantified by an easy-to-use symptom-based score reflecting acute phase disease burden and general psychological predisposition. The PCS score thus holds promise to facilitate the clinical diagnosis of PCS, scientific studies of its natural course, and the development of therapeutic interventions. Funding: The COVIDOM study is funded by the Network University Medicine (NUM) as part of the National Pandemic Cohort Network (NAPKON).
D. Medenwald,
T. Brunner,
H. Christiansen and
et al,
"Shift of radiotherapy use during the first wave of the COVID-19 pandemic? An analysis of German inpatient data",
Strahlenther Onkol,
vol. 198,
no. 4,
pp. 334—345,
2022.
| DOI: | 10.1007/s00066-021-01883-1 |
C. Schug,
F. Geiser,
N. Hiebel,
P. Beschoner,
L. Jerg-Bretzke,
K. Weidner,
E. Morawa and
Y. Erim,
"Sick Leave and Intention to Quit the Job among Nursing Staff in German Hospitals during the COVID-19 Pandemic",
International Journal of Environmental Research and Public Health,
vol. 19,
no. 4,
pp. 1947,
Feb.
2022.
| DOI: | 10.3390/ijerph19041947 |
| Datei: |  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872054/pdf/ijerph-19-01947.pdf |
C. Koll,
S. Hopff,
T. Meurers,
C. Lee,
M. Kohls,
C. Stellbrink,
C. Thibeault,
L. Reinke,
S. Steinbrecher,
S. Schreiber and
D. Stahl,
"Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients",
Sci Data,
vol. 9,
no. 1,
pp. 776,
2022.
| DOI: | 10.1038/s41597-022-01669-9 |
C. Koll,
S. Hopff and
T. Meurers,
"Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients.",
Sci Data 9, 776,
2022.
| DOI: | 10.1038/s41597-022-01669-9 |
M. Mayer,
S. Zellmer,
J. Zenk and
et al,
"Status quo after one year of COVID-19 pandemic in otolaryngological hospital-based departments and private practices in Germany",
Eur Arch Otorhinolaryngol,
vol. 279,
no. 2,
2022.
| DOI: | 10.1007/s00405-021-06992-2 |
H. Hoven,
N. Dragano,
P. Angerer,
C. Apfelbacher,
I. Backhaus,
B. Hoffmann,
A. Icks,
S. Wilm,
F. Fangerau and
F. Söhner,
"Striving for health equality: The importance of social determinants of health and ethical considerations in pandemic preparedness planning",
International Journal of Public Health,
vol. 67,
pp. 1604542,
2022.
| DOI: | 10.3389/ijph.2022.1604542 |
L. Peter and
et al,
"Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients",
Molecular therapy. Methods & clinical development,
vol. 25,
pp. 52–73,
2022.
| DOI: | 10.1016/j.omtm.2022.02.012 |
J. Gruendner,
N. Deppenwiese,
M. Folz,
T. Köhler,
B. Kroll,
H. Prokosch,
L. Rosenau,
M. Rühle,
M. Scheidl,
C. Schüttler,
B. Sedlmayr,
A. Twrdik,
A. Kiel and
R. W. Majeed,
"The Architecture for a feasibility query portal for distributed COVID-19 Fast Healthcare Interoperability Resources (FHIR) patient data repositories: Design and Implementation Study",
JMIR Medical Informatics,
vol. 10,
no. 5,
pp. e36709,
Mai
2022.
| DOI: | https://doi.org/10.2196/36709 |
| Pubmed: | 35486893 |
T. Czypionka,
E. N. Iftekhar,
B. Prainsack,
V. Priesemann,
S. Bauer,
A. C. Valdez,
S. Cuschieri,
E. Glaab,
E. Grill,
J. Krutzinna,
C. Lionis,
H. Machado,
C. Martins,
G. N. Pavlakis,
M. Perc,
E. Petelos,
M. Pickersgill,
A. Skupin,
E. Schernhammer,
E. Szczurek,
S. Tsiodras,
P. Willeit and
P. Wilmes,
"The benefits, costs and feasibility of a low incidence COVID-19 strategy",
The Lancet Regional Health-Europe,
vol. 13,
pp. 100294,
2022.
| DOI: | 10.1016/j.lanepe.2021.100294 |
S. Krasemann,
U. Haferkamp,
S. Pfefferle and
et al,
"The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2",
Stem Cell Reports,
vol. 17,
pp. 307-320,
2022.
| DOI: | 10.1016/j.stemcr.2021.12.011 |
P. Tafforeau,
W. Wagner and
et al,
"The Bronchial Circulation in COVID-19 Pneumonia",
Am J Respir Crit Care Med,
vol. 205,
pp. 121-125,
2022.
| DOI: | 10.1164/rccm.202103-0594IM |
P. Tafforeau,
W. Wagner,
C. Walsh,
C. Werlein,
M. Kühnel and
et al,
"The Bronchial Circulation in COVID-19 Pneumonia",
American Journal of Respiratory and Critical Care,
vol. 205,
pp. 121-125,
Jan.
2022.
| DOI: | 10.1164/rccm.202103-0594IM |
[en]
H. Prokosch,
T. Bahls,
M. Bialke,
J. Eils,
C. Fegeler,
J. Gruendner,
B. Haarbrandt,
C. Hampf,
W. Hoffmann,
H. Hund,
M. Kampf,
L. A. Kapsner,
P. Kasprzak,
O. Kohlbacher,
D. Krefting,
J. M. Mang,
M. Marschollek,
S. Mate,
A. Müller,
F. Prasser,
J. Sass,
S. Semler,
H. Stenzhorn,
S. Thun,
S. Zenker and
R. Eils,
"The COVID-19 Data Exchange Platform of the German university
medicine",
Stud. Health Technol. Inform.,
vol. 294,
pp. 674—678,
Mai
2022.
Abstract:
COVID-19 has challenged the healthcare systems worldwide. To quickly identify successful diagnostic and therapeutic approaches large data sharing approaches are inevitable. Though organizational clinical data are abundant, many of them are available only in isolated silos and largely inaccessible to external researchers. To overcome and tackle this challenge the university medicine network (comprising all 36 German university hospitals) has been founded in April 2020 to coordinate COVID-19 action plans, diagnostic and therapeutic strategies and collaborative research activities. 13 projects were initiated from which the CODEX project, aiming at the development of a Germany-wide Covid-19 Data Exchange Platform, is presented in this publication. We illustrate the conceptual design, the stepwise development and deployment, first results and the current status.
Abstract:
COVID-19 has challenged the healthcare systems worldwide. To quickly identify successful diagnostic and therapeutic approaches large data sharing approaches are inevitable. Though organizational clinical data are abundant, many of them are available only in isolated silos and largely inaccessible to external researchers. To overcome and tackle this challenge the university medicine network (comprising all 36 German university hospitals) has been founded in April 2020 to coordinate COVID-19 action plans, diagnostic and therapeutic strategies and collaborative research activities. 13 projects were initiated from which the CODEX project, aiming at the development of a Germany-wide Covid-19 Data Exchange Platform, is presented in this publication. We illustrate the conceptual design, the stepwise development and deployment, first results and the current status.
[en]
M. Schons,
L. Pilgram,
J. Reese,
M. Stecher,
G. Anton,
K. S. Appel,
T. Bahmer,
A. Bartschke,
C. Bellinghausen,
I. Bernemann,
M. Brechtel,
F. Brinkmann,
C. Brünn,
C. Dhillon,
C. Fiessler,
R. Geisler,
E. Hamelmann,
S. Hansch,
F. Hanses,
S. Hanß,
S. Herold,
R. Heyder,
A. Hofmann,
S. M. Hopff,
A. Horn,
C. Jakob,
S. Jiru-Hillmann,
T. Keil,
Y. Khodamoradi,
M. Kohls,
M. Kraus,
D. Krefting,
S. Kunze,
F. Kurth,
W. Lieb,
L. J. Lippert,
R. Lorbeer,
B. Lorenz-Depiereux,
C. Maetzler,
O. Miljukov,
M. Nauck,
D. Pape,
V. Püntmann,
L. Reinke,
C. Römmele,
S. Rudolph,
J. Sass,
C. Schäfer,
J. Schaller,
M. Schattschneider,
C. Scheer,
M. Scherer,
S. Schmidt,
J. Schmidt,
K. Seibel,
D. Stahl,
F. Steinbeis,
S. Störk,
M. Tauchert,
J. J. Tebbe,
C. Thibeault,
N. Toepfner,
K. Ungethüm,
I. Vadasz,
H. Valentin,
S. Wiedmann,
T. Zoller,
E. Nagel,
M. Krawczak,
C. Kalle,
T. Illig,
S. Schreiber,
M. Witzenrath,
P. Heuschmann,
J. J. Vehreschild and
N. R. Group,
"The German National Pandemic Cohort Network (NAPKON):
rationale, study design and baseline characteristics",
Eur. J. Epidemiol.,
vol. 37,
no. 8,
pp. 849—870,
Aug.
2022.
Springer Science and Business Media LLC.
Abstract:
The German government initiated the Network University Medicine (NUM) in early 2020 to improve national research activities on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. To this end, 36 German Academic Medical Centers started to collaborate on 13 projects, with the largest being the National Pandemic Cohort Network (NAPKON). The NAPKON's goal is creating the most comprehensive Coronavirus Disease 2019 (COVID-19) cohort in Germany. Within NAPKON, adult and pediatric patients are observed in three complementary cohort platforms (Cross-Sectoral, High-Resolution and Population-Based) from the initial infection until up to three years of follow-up. Study procedures comprise comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes and biosampling. The three cohort platforms build on four infrastructure core units (Interaction, Biosampling, Epidemiology, and Integration) and collaborations with NUM projects. Key components of the data capture, regulatory, and data privacy are based on the German Centre for Cardiovascular Research. By April 01, 2022, 34 university and 40 non-university hospitals have enrolled 5298 patients with local data quality reviews performed on 4727 (89%). 47% were female, the median age was 52 (IQR 36-62-) and 50 pediatric cases were included. 44% of patients were hospitalized, 15% admitted to an intensive care unit, and 12% of patients deceased while enrolled. 8845 visits with biosampling in 4349 patients were conducted by April 03, 2022. In this overview article, we summarize NAPKON's design, relevant milestones including first study population characteristics, and outline the potential of NAPKON for German and international research activities.Trial registration https://clinicaltrials.gov/ct2/show/NCT04768998 . https://clinicaltrials.gov/ct2/show/NCT04747366 . https://clinicaltrials.gov/ct2/show/NCT04679584.
| DOI: | 10.1007/s10654-022-00896-z |
| Pubmed: | 35904671 |
Abstract:
The German government initiated the Network University Medicine (NUM) in early 2020 to improve national research activities on the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic. To this end, 36 German Academic Medical Centers started to collaborate on 13 projects, with the largest being the National Pandemic Cohort Network (NAPKON). The NAPKON's goal is creating the most comprehensive Coronavirus Disease 2019 (COVID-19) cohort in Germany. Within NAPKON, adult and pediatric patients are observed in three complementary cohort platforms (Cross-Sectoral, High-Resolution and Population-Based) from the initial infection until up to three years of follow-up. Study procedures comprise comprehensive clinical and imaging diagnostics, quality-of-life assessment, patient-reported outcomes and biosampling. The three cohort platforms build on four infrastructure core units (Interaction, Biosampling, Epidemiology, and Integration) and collaborations with NUM projects. Key components of the data capture, regulatory, and data privacy are based on the German Centre for Cardiovascular Research. By April 01, 2022, 34 university and 40 non-university hospitals have enrolled 5298 patients with local data quality reviews performed on 4727 (89%). 47% were female, the median age was 52 (IQR 36-62-) and 50 pediatric cases were included. 44% of patients were hospitalized, 15% admitted to an intensive care unit, and 12% of patients deceased while enrolled. 8845 visits with biosampling in 4349 patients were conducted by April 03, 2022. In this overview article, we summarize NAPKON's design, relevant milestones including first study population characteristics, and outline the potential of NAPKON for German and international research activities.Trial registration https://clinicaltrials.gov/ct2/show/NCT04768998 . https://clinicaltrials.gov/ct2/show/NCT04747366 . https://clinicaltrials.gov/ct2/show/NCT04679584.
P. Borusiak,
Y. Mazheika,
S. Bauer,
E. Haberlandt,
I. Krois,
C. Fricke,
L. Simon,
P. Beschoner,
L. Jerg-Bretzke,
F. Geiser,
N. Hiebel,
K. Weidner,
E. Morawa and
Y. Erim,
"The impact of the COVID-19 pandemic on pediatric developmental services: a cross-sectional study on overall burden and mental health status",
Arch Public Health,
vol. 80,
no. 1,
pp. 113,
2022.
J. Hannemann,
Y. Erim,
E. Morawa,
L. Jerg-Bretzke,
P. Beschoner,
F. Geiser,
N. Hiebel,
K. Weidner and
S. Steudte-Schmiedgen,
"The impact of the COVID-19 pandemic on the mental health of medical staff considering the interplay of pandemic burden and psychosocial resources-A rapid systematic review",
PLoS One,
vol. 17,
no. 2,
pp. e0264290,
2022.
| DOI: | 10.1371/journal.pone.0264290 |
A. Schreiber,
D. Viemann,
J. Schöning,
S. Schloer,
A. Mecate Zambrano and
e. a. Brunotte,
"The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses",
Cell Mol Life Sci,
vol. 79,
pp. 65,
2022.
| DOI: | 10.1007/s00018-021-03917-x |
P. R. Wratil,
M. Stern,
A. Priller and
et al,
"Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern",
Nat Med,
2022.
| DOI: | 10.1038/s41591-022-01715-4 |
M. Voigtlaender,
C. Edler,
M. Gerling,
J. Schädler,
B. Ondruschka,
A. S. Schröder,
J. Sperhake,
S. Ehrhardt,
L. Wang,
M. Haddad,
V. Kiencke,
T. Renné,
K. Roedl,
S. Kluge,
D. Wichmann and
F. Länger,
"Thromboembolic events in deceased patients with proven SARS-CoV-2 infection: Frequency, characteristics and risk factors",
Thrombosis Research,
vol. 218,
pp. 171—176,
Okt.
2022.
Abstract:
Unlabelled Image
| DOI: | 10.1016/j.thromres.2022.08.021 |
| Datei: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420077/ |
Abstract:
Unlabelled Image
[eng]
J. C. Kamp,
L. Neubert,
H. Stark,
C. Werlein,
J. Fuge,
A. Haverich,
A. Tzankov,
K. Steinestel,
J. Friemann,
P. Boor,
K. Junker,
M. M. Hoeper,
T. Welte,
F. Laenger,
M. P. Kuehnel and
D. D. Jonigk,
"Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19",
International Journal of Molecular Sciences,
vol. 23,
no. 3,
pp. 1583,
Jan.
2022.
Abstract:
(1) Background: In COVID-19 survivors there is an increased prevalence of pulmonary fibrosis of which the underlying molecular mechanisms are poorly understood; (2) Methods: In this multicentric study, n = 12 patients who succumbed to COVID-19 due to progressive respiratory failure were assigned to an early and late group (death within ≤7 and \textgreater7 days of hospitalization, respectively) and compared to n = 11 healthy controls; mRNA and protein expression as well as biological pathway analysis were performed to gain insights into the evolution of pulmonary fibrogenesis in COVID-19; (3) Results: Median duration of hospitalization until death was 3 (IQR25-75, 3-3.75) and 14 (12.5-14) days in the early and late group, respectively. Fifty-eight out of 770 analyzed genes showed a significantly altered expression signature in COVID-19 compared to controls in a time-dependent manner. The entire study group showed an increased expression of BST2 and IL1R1, independent of hospitalization time. In the early group there was increased activity of inflammation-related genes and pathways, while fibrosis-related genes (particularly PDGFRB) and pathways dominated in the late group; (4) Conclusions: After the first week of hospitalization, there is a shift from pro-inflammatory to fibrogenic activity in severe COVID-19. IL1R1 and PDGFRB may serve as potential therapeutic targets in future studies.
| DOI: | 10.3390/ijms23031583 |
Abstract:
(1) Background: In COVID-19 survivors there is an increased prevalence of pulmonary fibrosis of which the underlying molecular mechanisms are poorly understood; (2) Methods: In this multicentric study, n = 12 patients who succumbed to COVID-19 due to progressive respiratory failure were assigned to an early and late group (death within ≤7 and \textgreater7 days of hospitalization, respectively) and compared to n = 11 healthy controls; mRNA and protein expression as well as biological pathway analysis were performed to gain insights into the evolution of pulmonary fibrogenesis in COVID-19; (3) Results: Median duration of hospitalization until death was 3 (IQR25-75, 3-3.75) and 14 (12.5-14) days in the early and late group, respectively. Fifty-eight out of 770 analyzed genes showed a significantly altered expression signature in COVID-19 compared to controls in a time-dependent manner. The entire study group showed an increased expression of BST2 and IL1R1, independent of hospitalization time. In the early group there was increased activity of inflammation-related genes and pathways, while fibrosis-related genes (particularly PDGFRB) and pathways dominated in the late group; (4) Conclusions: After the first week of hospitalization, there is a shift from pro-inflammatory to fibrogenic activity in severe COVID-19. IL1R1 and PDGFRB may serve as potential therapeutic targets in future studies.
J. Kamp,
L. Neubert and
et al,
"Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19",
Int J Mol Sci,
vol. 23,
2022.
| DOI: | 10.3390/ijms23031583 |
A. Wulff,
P. Biermann,
T. Landesberger,
T. Baumgartl,
C. Schmidt,
K. Schick,
P. Waldstein,
Y. Zhu,
D. Krefting,
S. Scheithauer and
M. Marschollek,
"Tracing COVID-19 Infection Chains Within Healthcare Institutions - Another Brick in the Wall Against SARS-CoV-2",
Studies in health technology and informatics,
vol. 290,
pp. 699—703,
2022.
Abstract:
Early anticipation of COVID-19 infection chains within hospitals is of high importance for initiating suitable measures at the right time. Infection control specialists can be supported by application systems able of consolidating and analyzing heterogeneous, up-to-now non-standardized and distributed data needed for tracking COVID-19 infections and infected patients' hospital contacts. We developed a system, Co-Surv-SmICS, assisting in infection chain detection, in an open and standards-based way to ensure reusability of the system across institutions. Data is modelled in alignment to various national modelling initiatives and consensus data definitions, queried in a standardized way by the use of OpenEHR as information modelling standard and its associated model-based query language, analyzed and interactively visualized in the application. A first version has been published and will be enhanced with further features and evaluated in detail with regard to its potentials to support specialists during their work against SARS-CoV-2.
| DOI: | 10.3233/SHTI220168 |
Abstract:
Early anticipation of COVID-19 infection chains within hospitals is of high importance for initiating suitable measures at the right time. Infection control specialists can be supported by application systems able of consolidating and analyzing heterogeneous, up-to-now non-standardized and distributed data needed for tracking COVID-19 infections and infected patients' hospital contacts. We developed a system, Co-Surv-SmICS, assisting in infection chain detection, in an open and standards-based way to ensure reusability of the system across institutions. Data is modelled in alignment to various national modelling initiatives and consensus data definitions, queried in a standardized way by the use of OpenEHR as information modelling standard and its associated model-based query language, analyzed and interactively visualized in the application. A first version has been published and will be enhanced with further features and evaluated in detail with regard to its potentials to support specialists during their work against SARS-CoV-2.
S. Stillfried,
B. Freeborn,
S. Windeck and
P. Boor,
"Update zur kooperativen autopsiebasierten Forschung in der deutschen Pathologie, Neuropathologie und Gerichtsmedizin",
Pathologie (Heidelberg, Germany),
vol. 43,
no. Suppl 1,
pp. 101—105,
2022.
Abstract:
Hintergrund Obduktionen sind ein wichtiges Instrument zum Verständnis von Krankheiten, einschließlich COVID-19. Material und Methoden Das im April 2020 eingerichtete und gestartete Deutsche Register für COVID-19-Obduktionen (DeRegCOVID) dient als elektronisches Rückgrat des Nationalen Obduktionsnetzwerks (NATON), das Anfang 2022 im Anschluss an DEFEAT PANDEMIcs gestartet worden ist. Ergebnisse Die vernetzte, kollaborative Obduktionsforschung des NATON-Konsortiums wird durch eine beispiellose Zusammenarbeit von 138 Personen an mehr als 35 universitären und nichtuniversitären Obduktionszentren ermöglicht, durch die Daten, einschließlich Daten zu Biomaterialien aus Pathologie, Neuropathologie und Rechtsmedizin, im DeRegCOVID gesammelt sowie gewebebasierte Forschung und Methodenentwicklung betrieben werden. Aus den teilnehmenden Obduktionszentren sind inzwischen mehr als 145 Publikationen hervorgegangen, die verschiedene grundlagenwissenschaftliche und klinische Aspekte von COVID-19 beleuchten, z. B. thromboembolische Ereignisse, Organtropismus, Nachweismethoden von SARS-CoV‑2 oder die Infektiosität von SARS-CoV‑2 bei der Obduktion. Schlussfolgerungen Die teilnehmenden Zentren haben den hohen Wert der Autopsie und der aus der Autopsie gewonnenen Daten und Biomaterialien für die moderne Medizin unter Beweis gestellt. Die geplante langfristige Fortführung und Weiterentwicklung des Registers und Netzwerks und die offene und partizipative Gestaltung ermöglichen es, alle interessierten Partner miteinzubeziehen.
| DOI: | 10.1007/s00292-022-01117-w |
| Datei: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483541/ |
Abstract:
Hintergrund Obduktionen sind ein wichtiges Instrument zum Verständnis von Krankheiten, einschließlich COVID-19. Material und Methoden Das im April 2020 eingerichtete und gestartete Deutsche Register für COVID-19-Obduktionen (DeRegCOVID) dient als elektronisches Rückgrat des Nationalen Obduktionsnetzwerks (NATON), das Anfang 2022 im Anschluss an DEFEAT PANDEMIcs gestartet worden ist. Ergebnisse Die vernetzte, kollaborative Obduktionsforschung des NATON-Konsortiums wird durch eine beispiellose Zusammenarbeit von 138 Personen an mehr als 35 universitären und nichtuniversitären Obduktionszentren ermöglicht, durch die Daten, einschließlich Daten zu Biomaterialien aus Pathologie, Neuropathologie und Rechtsmedizin, im DeRegCOVID gesammelt sowie gewebebasierte Forschung und Methodenentwicklung betrieben werden. Aus den teilnehmenden Obduktionszentren sind inzwischen mehr als 145 Publikationen hervorgegangen, die verschiedene grundlagenwissenschaftliche und klinische Aspekte von COVID-19 beleuchten, z. B. thromboembolische Ereignisse, Organtropismus, Nachweismethoden von SARS-CoV‑2 oder die Infektiosität von SARS-CoV‑2 bei der Obduktion. Schlussfolgerungen Die teilnehmenden Zentren haben den hohen Wert der Autopsie und der aus der Autopsie gewonnenen Daten und Biomaterialien für die moderne Medizin unter Beweis gestellt. Die geplante langfristige Fortführung und Weiterentwicklung des Registers und Netzwerks und die offene und partizipative Gestaltung ermöglichen es, alle interessierten Partner miteinzubeziehen.
C. Schug,
Y. Erim,
F. Geiser,
N. Hiebel,
P. Beschoner,
L. Jerg-Bretzke,
K. Weidner,
S. Steudte-Schmiedgen,
A. Borho,
M. Lieb and
E. Morawa,
"Vaccination willingness against COVID-19 among healthcare workers in Germany: Results from a University Medicine Network survey between November 2020 and January 2021",
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz,
vol. 65,
no. 1,
pp. 74—85,
Jan.
2022.
| DOI: | 10.1007/s00103-021-03418-6 |
| Datei: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458789/pdf/103_2021_Article_3418.pdf |
C. Struwe,
M. Golinski,
C. Grimm,
S. Dickel,
K. Grummich,
M. Nothacker,
S. Voigt-Radloff,
J. Meerpohl and
O. Moerer,
"Vergleich und Bewertung internationaler Leitlinien zur Behandlung schwerer Verläufe von SARS-CoV-2-Infektionen",
Dtsch Arztebl Int,
vol. 119,
pp. 23-30,
2022.
| DOI: | 10.3238/arztebl.m2022.0006 |
K. Mayer,
"Pandemic Disruptions and Transnational Care Relations: Towards Closing the “Care Gap” in International Relations Theories"
in In the Realm of Corona Normativities II, Gephart, W, Eds.
Verlag Vitorrio Klostermann,
2022.
S. Dickel,
C. Grimm,
M. Popp,
C. Struwe,
A. Sachkova,
M. Golinski,
C. Seeber,
F. Fichtner,
D. Heise,
P. Kranke,
W. Meissner,
S. Laudi,
S. Voigt-Radloff,
J. Meerpohl,
O. Moerer and
Group On Behalf Of The German CEOsys Study,
"A Nationwide Cross-Sectional Online Survey on the Treatment of COVID-19-ARDS: High Variance in Standard of Care in German ICUs",
J Clin Med,
vol. 10,
no. 15,
pp. 3363,
Jul.
2021.
| DOI: | 10.3390/jcm10153363 |
K. Evert,
T. Dienemann,
C. Brochhausen,
D. Lunz,
M. Lubnow,
M. Ritzka and
et al,
"Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation",
Virchows Arch,
vol. 479,
pp. 97-108,
Jan.
2021.
| DOI: | https://doi.org/10.1007/s00428-020-03014-0 |
C. Grimm,
S. Dickel,
A. Sachkova,
M. Popp,
M. Golinksi,
F. Fichtner,
P. Kranke,
C. Seeber,
S. Laudi,
S. Voigt-Radloff and
O. Moerer,
"Targeted Minimal Staff-to-Patient Ratios Are Unachievable - A Nationwide Survey in German ICUs During the COVID-19 Pandemic",
Cureus,
vol. 13,
no. 6,
pp. e15755,
Jun.
2021.
| DOI: | 10.7759/cureus.15755 |
C. Holzmann-Littig,
M. C. Braunisch,
P. Kranke,
M. Popp,
C. Seeber,
F. Fichtner,
B. Littig,
J. Carbajo-Lozoya,
T. Frank,
J. J. Meerpohl,
B. Haller and
C. Schmaderer,
"COVID-19 Vaccination Acceptance and Hesitancy among Healthcare Workers in Germany",
Vaccines (Basel),
vol. 9,
no. 7,
pp. 777,
Jul.
2021.
| DOI: | 10.3390/vaccines9070777 |
C. Werlein,
F. Länger,
M. Kühnel and
D. Jonigk,
"COVID-19: Auswirkungen auf Lunge und Herz",
Pathologe,
vol. 42,
pp. 164-171,
Feb.
2021.
| DOI: | https://doi.org/10.1007/s00292-021-00918-9 |
M. Jansky,
F. Schade,
N. Rieder,
D. Lohrmann,
C. Gebel and
D. Stahl,
"‘It felt like a black hole, great uncertainty, but we have to take care for our patients’–Qualitative findings on the effects of the COVID-19 pandemic on specialist palliative home care",
PLOS ONE,
vol. 16,
no. 12,
pp. e0260767,
2021.
| DOI: | 10.1371/journal.pone.0260767 |
K. Schloesser,
S. T. Simon,
B. Pauli and
D. Stahl,
"“Saying goodbye all alone with no close support was difficult”- Dying during the COVID-19 pandemic: an online survey among bereaved relatives about end-of-life care for patients with or without SARS-CoV2 infection",
BMC Health Serv Res,
vol. 21,
no. 998,
2021.
| DOI: | 10.1186/s12913-021-06987-z |
C. Gebel,
L. Kloppenburg,
M. K. Jansky,
F. Nauck,
F. Schade and
U. Weddin,
"„Es waren Kreativität und Umdenken erforderlich.“ Auswirkungen der COVID-19 Pandemie auf die spezialisierte ambulante Palliativversorgung (SAPV). Eine bundesweite Onlinebefragung",
Gesundheitswesen,
2021.
| DOI: | 10.1055/a-1714-8336 |
M. Reichardt,
P. Moller Jensen,
A. Bjorholm Dahl,
H. Shah,
F. Länger,
C. Werlein,
M. P. Kuehnel,
D. Jonigk and
T. Salditt,
"3D virtual histopathology of cardiac tissue from Covid-19 patients based on phase-contrast X-ray tomography",
eLife,
vol. 10,
pp. e71359,
2021.
Abstract:
For the first time, we have used phase-contrast X-ray tomography to characterize the three-dimensional (3d) structure of cardiac tissue from patients who succumbed to Covid-19. By extending conventional histopathological examination by a third dimension, the delicate pathological changes of the vascular system of severe Covid-19 progressions can be analyzed, fully quantified and compared to other types of viral myocarditis and controls. To this end, cardiac samples with a cross-section of 3.5mm were scanned at a laboratory setup as well as at a parallel beam setup at a synchrotron radiation facility the synchrotron in a parallel beam configuration. The vascular network was segmented by a deep learning architecture suitable for 3d datasets (V-net), trained by sparse manual annotations. Pathological alterations of vessels, concerning the variation of diameters and the amount of small holes, were observed, indicative of elevated occurrence of intussusceptive angiogenesis, also confirmed by high-resolution cone beam X-ray tomography and scanning electron microscopy. Furthermore, we implemented a fully automated analysis of the tissue structure in the form of shape measures based on the structure tensor. The corresponding distributions show that the histopathology of Covid-19 differs from both influenza and typical coxsackie virus myocarditis.
| DOI: | 10.7554/eLife.71359 |
| Datei: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747495/ |
Abstract:
For the first time, we have used phase-contrast X-ray tomography to characterize the three-dimensional (3d) structure of cardiac tissue from patients who succumbed to Covid-19. By extending conventional histopathological examination by a third dimension, the delicate pathological changes of the vascular system of severe Covid-19 progressions can be analyzed, fully quantified and compared to other types of viral myocarditis and controls. To this end, cardiac samples with a cross-section of 3.5mm were scanned at a laboratory setup as well as at a parallel beam setup at a synchrotron radiation facility the synchrotron in a parallel beam configuration. The vascular network was segmented by a deep learning architecture suitable for 3d datasets (V-net), trained by sparse manual annotations. Pathological alterations of vessels, concerning the variation of diameters and the amount of small holes, were observed, indicative of elevated occurrence of intussusceptive angiogenesis, also confirmed by high-resolution cone beam X-ray tomography and scanning electron microscopy. Furthermore, we implemented a fully automated analysis of the tissue structure in the form of shape measures based on the structure tensor. The corresponding distributions show that the histopathology of Covid-19 differs from both influenza and typical coxsackie virus myocarditis.
M. Reichardt,
P. Moller Jensen and
et al,
"3D virtual histopathology of cardiac tissue from Covid-19 patients based on phase-contrast X-ray tomography",
Elife,
vol. 10,
pp. e71359,
2021.
| DOI: | 10.7554/eLife.71359 |
N. Vesper and
et al,
"A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants",
Frontiers in immunology,
vol. 12,
2021.
| DOI: | 10.3389/fimmu.2021.730766 |
E. N. Iftekhar,
V. Priesemann,
R. Balling,
S. Bauer,
P. Beutels,
A. C. Valdez,
S. Cuschieri,
T. Czypionla,
U. Dumpis,
E. Glaab,
E. Grill,
C. Hanson,
P. Hotulainen,
P. Klimek,
M. Kretzschmar,
T. Krüger,
J. Krutzinna,
N. Low,
H. Machado,
C. Martins,
M. McKee,
S. B. Mohr,
A. Nassehi,
M. Perc,
E. Petelos,
M. Pickersgrill,
B. Prainsack,
J. Rocklöv,
E. Schernhammer,
A. Staines,
E. Szczurek,
S. Tsiodras,
S. Van Gucht and
P. Willeit,
"A look into the future of the COVID-19 pandemic in Europe: an expert consultation",
The Lancet Regional Health-Europe,
vol. 8,
pp. 100185,
2021.
| DOI: | 10.1016/j.lanepe.2021.100185 |
Z. Wang,
A. Cryar,
O. Lemke,
D. Ludwig,
P. Tober-Lau and
e. a. Helbig,
"A multiplex protein panel assay determines disease severity and is prognostic about outcome in COVID-19 patients",
medRxiv,
2021.
| DOI: | 10.1101/2021.12.03.21267253 |
M. Mahoney and
et al,
"A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells",
Proceedings of the National Academy of Sciences of the United States of America,
vol. 118,
2021.
| DOI: | 10.1073/pnas.2108728118 |
A. S. Peter and
et al,
"A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model",
European journal of immunology,
2021.
| DOI: | 10.1002/eji.202149374 |
A. S. Peter,
E. Roth,
S. R. Schulz and
et al,
"A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS‐CoV‐2 infection model",
Eur J Immunol,
2021.
| DOI: | 10.1002/eji.202149374 |
| Datei: | https://doi.org/10.1002/eji.202149374 |
W. Schuh and
et al,
"A surrogate cell-based SARS-CoV-2 spike blocking assay",
European journal of immunology,
2021.
| DOI: | 10.1002/eji.202149302 |
V. Demichev,
P. Tober-Lau,
O. Lemke,
T. Nazarenko,
C. Thibeault,
H. Whitwell,
A. Röhl,
A. Freiwald,
L. Szyrwiel,
D. Ludwig and
D. Stahl,
"A time-resolved proteomic and prognostic map of COVID-19",
Cell Syst,
vol. 12,
no. 8,
pp. 780—794.e7,
2021.
| DOI: | 10.1016/j.cels.2021.05.005 |
V. Demichev,
P. Tober-Lau,
O. Lemke,
T. Nazarenko,
C. Thibeault and
e. a. Whitwell,
"A time-resolved proteomic and prognostic map of COVID-19",
Cell Syst,
vol. 12,
pp. 780—+,
2021.